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Abstract
Background: The first-line treatment of a pelvic recurrence in a previously irradiated area is surgery. Unfortunately,
few patients are deemed operable, often due to the location of the recurrence, usually too close to the iliac
vessels, or the associated surgical morbidity. The objective of this study is to test the viability of robotic image-
guided radiotherapy as an alternative treatment in inoperable cases.
Methods: Sixteen patients previously treated with radiotherapy were reirradiated with CyberKnife® for lateral pelvic
lesions. Recurrences of primary rectal cancer (4 patients), anal canal (6), uterine cervix cancer (4), endometrial
cancer (1), and bladder carcinoma (1) were treated. The median dose of the previous treatment was 45 Gy (EqD2
range: 20 to 96 Gy). A total dose of 36 Gy in six fractions was delivered with the CyberKnife over three weeks. The
responses were evaluated according to RECIST criteria.
Results: Median follow-up was 10.6 months (1.9 to 20.5 months). The actuarial local control rate was 51.4% at one
year. Median disease-free survival was 8.3 months after CyberKnife treatment. The actuarial one-year survival rate
was 46%. Acute tolerance was limited to digestive grade 1 and 2 toxicities.
Conclusions: Robotic stereotactic radiotherapy can offer a short and well-tolerated treatment for lateral pelvic
recurrences in previously irradiated areas in patients otherwise not treatable. Efficacy and toxicity need to be
evaluated over the long term, but initial results are encouraging.
Background
Cancers such as prostate adenocarcinoma, epidermoid
carcinoma of the uterine cervix, and adenocarcinoma of
the rectum receive pelvic radiotherapy as part of their
initial treatment. Locoregional recurrence occurs in 3%
to 15% of patients treated for rectal adenocarcinoma [1]
and 1.5% to 40% of patients treated for carcinoma of the
uterine cervix [2]. Better systematic monitoring of these
pathologies, as well as progress in imaging, enabled ear-
lier diagnosis of locoregional pelvic recurrences. How-
ever, in cases of lateral pelvic recurrence, therapeutic
options are often limited. In these situations, surgery is
often proposed, but unfortunately, few patients are
found eligible because of the lateral location, the proxi-
mity of the iliac vessels and the associated surgical mor-
bidity. Traditionally, an invasion of the lateral pelvic
wall and/or envelopment of the iliac vessels are contra-
indications to a local radical procedure [3]. Without
treatment, these patients have a short life expectancy
and tend to experience symptoms, especially pain, with
their quality of life becoming extremely poor [4].
Recent progress in image-guided radiotherapy (IGRT)
has allowed a significant increase in the dose to the
tumor volume while decreasing the dose to the neigh-
boring organs at risk. Since June 2007, a robotic IGRT
system, the CyberKnife® (Accuray Incorporated, Sunny-
vale, California, USA) has been available at the Centre
Oscar Lambret in Lille, France. This system is capable
of delivering extracranial stereotactic radiotherapy with
millimetric precision [5-7]. Here, we report the tolerance
and feasibility of robotic IGRT for lateral pelvic recur-
rences based on our preliminary experience in 16
patients reirradiated with CyberKnife.
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Methods
Patients
Sixteen patients have been reirradiated with the Cyber-
Knife for lateral pelvic lesions at our center since June
2007. The primary diseases were six anal canal lesions,
four rectal cancers, four uterine cervical cancers, one
endometrial cancer, and one bladder carcinoma. Ten
women and six men were treated. The mean age at the
recurrence was 55 years (range, 35 to 70 years). These
patients had previously received, as part of their initial
treatment, pelvic radiotherapy in the form of external-
beam radiotherapy or brachytherapy. The median prior
dose was 45 Gy (range, 52 to 96 Gy). Patient character-
istics and biologically equivalent doses received by the
lateral pelvic wall are reported in Table 1.
Lateral pelvic recurrence
Pelvic recurrence was discovered during systematic ima-
ging examination for thirteen patients (example shown
in Figure 1) and by clinical symptoms such as pain for
three others. To rule out distant metastases, thoracic-
abdominal-pelvic CT and FDG-PET were performed
before CyberKnife treatment. The median disease-free
interval between initial treatment and recurrence was 27
months (range, 4 to 148 months). All referrals for
CyberKnife treatment were reviewed by a multidisciplin-
ary board. One patient presented with bilateral pelvic
recurrence from cervical cancer. Eight patients had che-
motherapy before stereotactic radiotherapy (three to 10
courses of chemotherapy). Six patients had local surgical
excisions. Five excisions were interrupted because of dif-
ficulties with neurovascular dissection and were conse-
quently classified R2 (incomplete macroscopic
resection). Three patients received radiation therapy
(mean 53.7 Gy, 36 to 66 Gy) to the pelvis as part of the
treatment for recurrence before CyberKnife treatment.
CyberKnife treatment
A vacuum mattress was used for immobilization during
imaging and throughout treatment. Contrast agent was
used for the planning CT. The gross tumor volume
(GTV) was contoured on a fused CT/MRI matrix. The
clinical target volume (CTV) was equal to GTV. The
planning, set-up and treatment were conducted using
Xsight® Spine (Accuray) tracking method available with
the CyberKnife system. Patient positioning and image
guidance was performed with Accuray’s Xsight Spine
algorithm with registration to the patient’s spine and
Table 1 Characteristics of patients treated with CyberKnife for pelvic re-irradiation.
Number (%) Mean (range) Comments
Patients 16
Sex (M/F) 6 (37%)/10 (63%)
Age* 55 (34 - 70 y.o.)
Primary disease







Chemotherapy 13 (81%) 9 concomitant; 4 adjuvant
Radiotherapy 14 (87%)
Dose* 45 Gy (20-75 Gy)
Eq D2*
Early side effects (a/b = 3 Gy) 45 Gy (33-58 Gy)
Late side effects (a/b = 10 Gy) 72 Gy (53-96 Gy)




Dose* 53.7 Gy (36-66 Gy)
Eq D2*
Early side effects (a/b = 3 Gy) 65 Gy (45-66 Gy)
Late side effects (a/b = 10 Gy) 106 Gy (72-110 Gy)
* Median value
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pelvic bones. The median size of the tumor targets was
34.5 mm (range, 14 to 50 mm). Planning target volume
included the CTV and a 3-mm margin due to the dis-
tance of the target from anatomical landmarks used for
the tracking process and the uncertainty that might
entail [8]. The treatment delivered a total dose of 36 Gy
in six fractions over three weeks with a 6 MeV beam.
The dose was prescribed to the 80% isodose line cover-
ing 95% of the PTV (Figure 2). Dose calculation was
performed using the Ray-Tracing algorithm. One patient
received concomitant Cetuximab combined with a plati-
num salt. One patient received 45 Gy in 3 fractions,
considering the location of the lesion, away from the
iliac vessels.
Follow-up and statistics
This was a single-institution retrospective study con-
ducted at the Centre Oscar Lambret. All subjects signed
an informed consent form prior to treatments. The
patients were followed systematically every 3 months
after CyberKnife treatment for a median follow-up of
10.6 months (1.9 to 20.5 months). Follow-up visits
included both clinical and laboratory tests. CTCAE v3.0
was used for scoring GI and GU toxicity. The responses
were evaluated according to RECIST v1.1 criteria on
CT-Scan performed every 3 months. The endpoints stu-
died were treatment feasibility, toxicity and preliminary
local control. Quality of life improvements based on
patient self-reports and pain relief based on discontinua-
tion of opiate usage were also examined. Local control,
overall survival and disease-free survival analysis were
carried out using the Kaplan-Meier method. Statistical
packages SPSS 13.0 (SPSS Inc., Chicago, IL, USA) were
used to perform the analysis.
Results
Feasibility
All patients were in excellent general condition at the
time of recurrence and CyberKnife treatment (WHO =
0/1 for 15 patients and WHO = 2 for one). Eight
patients described a sciatic pain at the time of diagnosis
of the recurrence. All these patients were taking opioid
pain medication before beginning irradiation. The med-
ian interval between the diagnosis of the recurrence and
the beginning of the CyberKnife treatment was 5.3
months (range, 1 to 31 months). All treatments were
delivered uneventfully as planned. The mean duration of
the sessions was 48 minutes (range, 32 to 75 min) for
Figure 1 Examples of pelvic recurrence in previously irradiated areas: (A) Rectal cancer recurrence near the right iliac vessels (B) Cervix
cancer recurrence near the left iliac vessels (C) Right pelvic anal canal recurrence (D) Rectal cancer recurrence previously (3 surgical clips visible).
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the sessions of 6 Gy and 78 min for the patient treated
in three 15-Gy sessions.
Efficacy
Median follow-up was 10.6 months (1.9 to 20.5 months).
The overall median survival after CyberKnife treatment
was 11.5 months and 25.7 months after diagnosis of the
pelvic recurrence. The actuarial one-year survival rate
was 46%. The one-year local control rate was 51.4%.
Treatment of adenocarcinoma tended to result in better
local control than squamous carcinoma (p = 0.09). The
time between initial disease and recurrence and between
recurrence and CyberKnife treatment did not modify
overall survival or local control. Median disease-free sur-
vival was 8.3 months after CyberKnife treatment. Dis-
ease-free survival rate at 6 months was 63% (95% IC: 49
to 77%) (Figure 3). Four of the eight patients (50%) with
pain described an improvement in terms of pain relief
at the end of radiotherapy. However discontinuation of
opioid treatment was never possible following the
treatment.
Toxicity
Acute toxicity was limited to grade 1 and 2 complica-
tions. One patient (6.25%) presented with nausea/
vomiting (grade 2), two patients (12.5%) with diarrhea
(grade 1) at the end of treatment and one patient
(6.25%) had an increase in pain (grade 1). One patient
(6.25%) experienced grade 2 digestive toxicity 3 months
post-treatment. A grade 2 edema on the ipsilateral leg
was described in one patient (6.25%) 3 months after
treatment. At six months, a patient (6.25%) presented
with grade 2 anorexia. To the date of this publication,
no grade 3 or grade 4 toxicity has been observed.
Discussion
We report a series of 16 patients treated for lateral
pelvic recurrences in the proximity of iliac vessels. The
one-year local control rate was 51.4% according to
RECIST criteria with a median follow-up of 10.6
months. The overall median survival after CyberKnife
treatment was 11.5 months and 25.7 months after diag-
nosis of the pelvic recurrence. It seemed that the
Figure 2 Dosimetry for pelvic stereotactic radiotherapy by CyberKnife for each patients presented in figure 1. Prescription to the 80%
isodose line covering 95% of the PTV.
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treatment delayed local disease progression in all cases
considering the rapid rate of progression commonly
observed with these lesions [9,10]. In addition, it pro-
vided quality of life benefits by improving pain control
in four patients based on self-reports. Tolerance of the
technique was excellent. No grade 3 or 4 toxicity was
observed. The toxicities described were essentially of
digestive nature with one anorexia, some nausea and
vomiting. There were no persistent urinary or gastroin-
testinal toxicities observed. Overall the feasibility of this
technique was good.
Our population was not homogenous in regard to the
histology of the primary lesion. Despite this variation, the
treatment challenges presented by lateral pelvic recur-
rences in a previously irradiated area in this cohort were
similar. The chance of survival also depended on the site of
the recurrence and the stage of the disease at diagnosis
rather than the pathology of the primary. Lateral pelvic
surgery is often difficult and highly risky. Operations often
have to be prematurely aborted, resulting in a type R2
resection (incomplete macroscopic resection) because of
the proximity of the iliac vessels. In our series, surgical
excision was attempted and failed to reach completion in
five patients due to difficulties posed by vascular dissection.
Suzuki et al. have reported that none of the patients
with recurrent rectal cancer who have undergone surgi-
cal excision survived even five years because of the
impossibility of applying sufficiently generous margins
[11]. Complete surgical removal may be the only hope
for long-term survival, yet comes with the price of sig-
nificant morbidity [12,13]. Curative surgical approach
can only be achieved when margins are negative for
microscopic extension of disease. In case of recurrences
of rectal adenocarcinoma, this can be achieved in about
45% of cases, ranging from 10% to 67% in the published
literature. Thus, resection of local recurrence usually
requires major surgery, involving removal of adjacent
pelvic organs. Operative morbidity varies from 22% to
100% [3]. Surgical treatment of pelvic recurrence in the
uterine cervix has also been reported. Surgical salvage is
feasible in only a small number of central recurrences
and that too involves all the associated morbidity and
mortality. Surgery, in most of these patients, amounts to
either anterior, posterior or total exenteration [9]. The
procedure is thus highly morbid and results in severe
quality of life challenges. In short, treatment remains a
challenge and no consensus exists as to an optimal
treatment approach [10].
Consequently, pelvic stereotactic radiotherapy repre-
sents an attractive alternative for patients otherwise not
Figure 3 The overall median survival after CyberKnife
treatment was 11.5 months and 25.7 months after diagnosis of
the pelvic recurrence. The actuarial one-year survival rate was 46%.
The one-year actuarial local control rate was 51.4%. Median disease-
free survival was 8.3 months after CyberKnife treatment.
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treatable. Robotic IGRT is now equipped with technol-
ogy capable of delivering ablative doses of radiation to
clinical targets with high conformality and homogeneity.
This may result in a more durable response of pelvic
recurrences in patients who have already received a
dose of pelvic irradiation and whose tumors are not
amenable to surgery.
There are several studies reporting on SBRT for pelvic
reirradiation for recurrent gynaecological cancer [14]
and recurrent rectal cancer [15]. Pelvic stereotactic re-
irradiation has been reported in the literature in an arti-
cle on treatment with CyberKnife of 23 patients with
recurrent rectal carcinoma four of whom had received
prior radiation [16]. In that report, which was a dose
escalation study, 16 of the recurrences were localized in
the lateral pelvic wall. Fiducial markers were employed
in the image-guided tracking of the targets. A geometric
expansion of 3 mm was applied to the GTV in all direc-
tions to obtain the PTV and the doses delivered ranged
from 16 Gy to 51 Gy. The five-year survival rate was
23.2% and overall median survival 37 months. The rate
of survival without progression at four years was 74.3%.
They reported a single grade-4 toxicity, a digestive track
perforation, in a patient who received 51 Gy in three
fractions. No specific toxicity was reported in the four
previously treated patients. A second study reported by
Kunos et al. included three cases of CyberKnife treat-
ment for recurrence of vulval epidermoid carcinoma fol-
lowing previous irradiation [17]. After positioning with
gold markers, a dose of 24 Gy was delivered over three
sessions of 8 Gy to the prescription isodose line of 70%
to 75%. The previous doses received by the pelvis ran-
ged from 45 to 74.6 Gy. The rate of local control at the
treated targets was 100%, but unfortunately all the
patients had recurrences outside of the irradiated fields.
More recently, a series of 38 patients treated by Cyber-
Knife to the pelvis was reported by the team of Muace-
vic et al [8]. The feasibility of this irradiation modality
without placement of pelvic fiducial markers has been
described as good. Seven patients had received previous
pelvic irradiation, but no stratified analysis of this popu-
lation was presented.
Other radiotherapy techniques have also been
reported that show differing degrees of efficacy and toxi-
city. Brachytherapy allows the delivery of the prescribed
dose to a well-defined volume. Reirradiation with bra-
chytherapy in the treatment of uterine cervical cancer,
either interstitially or more recently with high-dose rate
(HDR) technique, peri-operatively or not, have been
described [18-20]. In one series of 40 patients treated
for carcinoma of the uterine cervix, reirradiation by
means of interstitial brachytherapy was employed for 14
of the patients [21]. The rate of local control was 50%
with a minimum post-treatment period of 2 years.
Laparotomy was performed for all in the patient selec-
tion process. Gupta et al. reported a local control rate of
49% at three years in 15 patients that had previously
received pelvic irradiation [22]. Charra et al. have trea-
ted 78 patients for carcinoma of the uterine cervix or
endometrium [23]. They applied brachytherapy to the
vaginal vault for recurrences in patients who were
deemed eligible for this procedure. Thirty-seven percent
of their patients had received radiotherapy during their
initial treatment. The rate of local control at 5 years for
these patients was 47% compared with 61% for patients
without history of radiation treatment. Tolerance to this
technique was good, but brachytherapy is an invasive
technique requiring prolonged hospitalization and surgi-
cal intervention. Most importantly, this technique can
only be recommended for recurrences in patients who
are medically eligible and requires a rigorous patient
selection.
On the other hand, there are a many studies about the
treatment of recurrent adenocarcinoma of the rectum in
an irradiated area. These are most often treated in a
multimodal fashion, combining surgery with radiother-
apy (external beam, perioperative radiotherapy), and
chemotherapy. Tumor control rate at 3 years ranges
from 14 to 56% [24-27]. The advantage of perioperative
radiotherapy over other techniques has not been
demonstrated. The recurrence rate in irradiated fields
can be significant, described as up to 50% in the litera-
ture [28]. Intraoperative radiotherapy (IORT) has also
been described [29-32]. IORT may stall recuperation
from a macroscopically incomplete surgery [33]. One
series from the Mayo Clinic including 51 patients that
had received previous irradiation during their initial
treatment showed a lower five-year survival rate among
these patients with a history of previous irradiation
compared to radiation-naïve patients [34]. The rate of
local control and survival is greater when IORT is com-
bined with neoadjuvant concomitant chemoradiotherapy
and is only considered as part of a multimodality treat-
ment regimen, surgery being at the center of the treat-
ment despite associated difficulties. Other, less common
treatments have been described and are still in develop-
ment, such as hyperthermia [35-37].
One difficulty in our series was evaluation of local
response to the treatment using the RECIST criteria. In
fact, none of the patients demonstrated an unequivocal
response to the treatment on comparative follow-up
examinations. On the other hand, changes in the vascu-
larization patterns of the tumors, and particularly, a
decrease in uptake of contrast material were often
reported by radiologists in charge of interpreting the
imaging studies. We believe it is necessary to establish
more suitable and specific criteria for monitoring these
patients. Quality of life criteria are also important to
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take into account in the treatment of these patients, and
they are insufficiently studied [38].
Conclusions
Stereotactic radiotherapy by the robotic CyberKnife Sys-
tem can offer a brief and well-tolerated treatment for
lateral pelvic recurrences in an area previously irradiated
in non-operable patients otherwise not treatable. Long-
term efficacy and toxicity need to be evaluated, however,
the method is highly feasible. CyberKnife radiosurgery
represents a new radiotherapeutic modality for patients
with a history of previous pelvic irradiation. Additional
study of treatment parameters and clinical outcomes
including toxicity is planned.
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